We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Novel Autoantibody against Septin-3 Discovered in Neurological Disease

By LabMedica International staff writers
Posted on 27 Apr 2023
Print article
Image: septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes (Photo courtesy of EUROIMMUN)
Image: septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes (Photo courtesy of EUROIMMUN)

Septins are cytoskeletal proteins that play multiple roles in cell division, cellular polarization, morphogenesis, and membrane trafficking. Septin-5 and septin-7 are already known target antigens of autoantibodies in neurological diseases. Now, scientists have discovered autoantibodies against septin-3 in patients with paraneoplastic cerebellar ataxia.

In a collaborative study between EUROIMMUN (Lübeck, Germany), the University of Heidelberg (Heidelberg, Germany), and other German clinics, researchers analyzed three patient sera with similar immunofluorescence staining patterns on cerebellar and hippocampal sections. They identified septin-3, -5, -6, -7, and -11 as candidate target antigens using immunoprecipitation and mass spectrometry. These proteins were then expressed recombinantly in HEK293 cells either individually, as complexes, or in combinations missing individual septins. The cells were used in recombinant-cell indirect immunofluorescence assays (RC-IIFA) to detect corresponding autoantibodies.

The three patient sera reacted with recombinant cells co-expressing septin-3/5/6/7/11, while none of the control sera did. Different septin combinations confirmed the autoantibodies' specificity for septin-3. In RC-IIFA analyses, patient sera reacted only with cells expressing septin-3, either individually or in complexes. The specificity was further verified by eliminating tissue IIFA reactivity through prior neutralization of autoantibodies with recombinant septin-3. All three patients presented with progressive cerebellar syndrome and responded poorly to immunotherapy. All had cancer (2 melanomas and 1 small-cell lung cancer). Expression of septin-3 was demonstrated in resected tumor tissue available from one patient.

The authors concluded that septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes. Due to the different clinical phenotypes reported in patients with anti-septin-3, -5, and -7 autoimmunity, these autoantibodies may serve as markers for different clinical presentations. As a result, septin-3 IgG-associated autoimmune cerebellar ataxia might represent a new paraneoplastic neurological syndrome (PNS). The suggested strategy for determining anti-septin autoantibodies is RC-IIFA with the complex septin-3/5/6/7/11 as a screening tool to investigate serological samples with a characteristic staining pattern on neuronal tissue sections. Autoantibodies against individual septins can then be confirmed by RC-IIFA expressing single antigens.

Related Links:
EUROIMMUN 
University of Heidelberg

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.